Management of gout: Beyond allopurinol

Internal Medicine Journal

Volumn 40, Issue 8, 2010, Pages 545-553

  McGill, N W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

allopurinol; febuxostat; gout; rheumatology

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBENECID; URATE;

CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; URIC ACID BLOOD LEVEL;

ALLOPURINOL; ANIMALS; BIOLOGICAL MARKERS; DISEASE MANAGEMENT; GOUT; HUMANS; URIC ACID;

EID: 77955820284     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02293.x     Document Type: Review

References (67)

1. Weaver AL. Epidemiology of gout. Cleve Clin J Med 2008 75 (Suppl 5 S9 12.
2. Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J et al. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008 14 : 164 75.
3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987 82 : 421 6.
4. Taniguchi A, Kamatani N. Control of uric acid excretion and gout. Curr Opin Rheumatol 2008 20 : 192 7.
5. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008 372 : 1953 61.
6. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008 40 : 437 42.
7. Merriman TR, Xu X, Dalbeth N, Merriman ME, McCallum R, Waddell C et al. A role for the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Maori, Pacific island and Caucasian case-control cohorts. Intern Med J 2009 39 (Suppl 2 C19, A42.
8. Williams PT. Effects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active men. Am J Clin Nutr 2008 87 : 1480 7.
9. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Br Med J 2008 336 : 309 12.
10. Underwood M. Sugary drinks, fruit, and increased risk of gout. Dietary fructose could be a contributing factor. Br Med J 2008 336 : 285 6.
11. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med 2009 169 : 502 7.
12. Choi HK, Willett W, Curhan G. Coffee consumption and risk of incident gout in men. A prospective study. Arthritis Rheum 2007 56 : 2049 55.
13. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid. Arthritis Rheum 2005 52 : 283 9.
14. McGill NW, Dieppe PA. The role of serum and synovial fluid components in promotion of urate crystal formation. J Rheumatol 1991 18 : 1042 5.
15. Pascual E. Analysis of synovial fluid from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and gout. Br J Rheumatol 1992 31 (Suppl 2 219.
16. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout. Implications for therapy. Arthritis Rheum 2007 56 : 3183 8.
17. Popa-Nita O, Marois L, Paré G, Naccache PH. Crystal-induced neutrophil activation. X. Proinflammatory role of the tyrosine kinase Tec. Arthritis Rheum 2008 58 : 1866 76.
18. Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, Naot D et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interaction with stromal cells. Arthritis Rheum 2008 58 : 1854 65.
19. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009 15 : 22 4.
20. McGill NW, McGill VG. Quality assurance for synovial fluid examination for crystals - an improved method. Ann Rheum Dis 1997 56 : 504 6.
21. McGill NW, McGill VG. Synovial fluid examination for crystals. A 7 year continuous quality assurance program. Intern Med J 2006 36 (Suppl 2 A28.
22. Pascual E, Doherty M. Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate. Ann Rheum Dis 2009 68 : 3 7.
23. Schlesinger N, Baker DG, Schumacher HR. Serum uric acid during bouts of acute gouty arthritis. J Rheumatol 1997 24 : 2265 6.
24. Logan JA, Morrison E, McGill PK. Serum uric acid in acute gout. Ann Rheum Dis 1997 56 : 696 7.
25. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007 116 : 894 900.
26. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem 2008 54 : 273 84.
27. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology 2008 47 : 1567 70.
28. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008 19 : 2204 10.
29. Colvine K, Kerr AJ, McLachlan A, Gow P, Kumar S, Ly J et al. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. NZ Med J 2008 121 : 73 81.
30. Steele TH. Hyperuricemic nephropathies. Nephron 1999 81 (Suppl 1 45 9.
31. Yu TSF, Berger L, Dorph DJ, Smith H. Renal function in gout. V. Factors influencing the renal haemodynamics. Am J Med 1979 67 : 766 71.
32. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982 41 : 59 65.
33. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotrophic hormone. Drugs 2008 68 : 407 15.
34. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008 CD005521.
35. Ahern MJ, McCredie M, Reid C, Brooks PM, Gordon TP, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987 17 : 301 4.
36. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008 10 : 218 27.
37. Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol 2008 46 : 827 30.
38. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007 66 : 1683 4.
39. Tausche AK, Richter K, Grassler A, Hansel S, Roch B, Schroder HE. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 2004 63 : 1351 2.
40. Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout ? Arthritis Rheum 2007 57 : 1324 8.
41. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007 46 : 1372 4.
42. Zhang W, Doherty M, Bardin T, Pascuel E, Barskova V, Conaghan P et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 65 : 1312 24.
43. Schumacher HR, Chen LX. The practical management of gout. Cleve Clin J Med 2008 75 (Suppl 5 S22 5.
44. Owens D, Whelan B, McCarthy G. A survey of the management of gout in primary care. Ir Med J 2008 101 : 147 9.
45. Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008 67 : 609 13.
46. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008 28 : 437 43.
47. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008 31 : 643 65.
48. Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009 68 : 51 6.
49. Chung Y, Lu CY, Graham GG, Mant A, Day RO. Utilization of allopurinol in the Australian community. Intern Med J 2008 38 : 388 95.
50. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009 11 : 135 40.
51. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998 431 : 13 18.
52. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004 31 : 2429 32.
53. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 353 : 2450 61.
54. Reinders MK, Haagsma C, Van Roon EN, Delsing J, Jansen TL, Van de Laar MA et al. Dose-escalation of allopurinol versus benzbromarone in gout patients: a randomised controlled trial. EULAR Congress, Paris, 2009 OP-0157.
55. Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007 20 : 391 5.
56. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 76 : 47 56.
57. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006 33 : 1646 50.
58. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008 14 : 6 11.
59. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008 49 : 384 7.
60. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008 58 : 25 32.
61. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001 60 : 981 3.
62. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology 2009 48 : 188 94.
63. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. A twenty-eight-day, multicentre, phase II, randomised, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005 52 : 916 23.
64. Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Ipsen sponsored symposium, EULAR Congress, Paris, 13 June, 2008.
65. Department of Health and Human Services, United States Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Drugs Advisory Committee Meeting. 24 November 2008. Silver Spring, MD, USA.
66. Oldfield V, Perry CM. Rasburicase: a review of its use in the management of anticancer therapy induced hyperuricemia. Drugs 2006 66 : 529 45.
67. Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007 34 : 2093 8.